Biocon Limited

Societe Generale bought 16,25,000 shares of Biocon for ₹65.00 Cr at ₹400.00 apiece in a block deal. This transaction was part of a larger block deal where Mylan Inc. exited its entire 5.64% stake in Biocon.

A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.

French global investment bank with around EUR 1.6 trillion in assets. India FPI activity covers proprietary, market-making and client flows in listed Indian equities.